BioSpace News Archive

Spectrum Solutions, LLC announced the U.S. Food and Drug Administration has extended its Emergency Use Authorization for the SDNA-1000 Saliva Collection Device to include the unsupervised self-collection of saliva for COVID-19 testing.

SINOMED, a leading international medical device company, announced the first commercial implantation of the HT Supreme® Drug-Eluting Stent at University Hospital Galway in partnership with the National University of Ireland Galway, marking the start of the European launch.

Eli Lilly and Company announced executive leadership changes and the creation of neuroscience and immunology business units.

Xilio Therapeutics, Inc., a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, announced the appointment of biotech executive Sara Bonstein, chief financial officer of Insmed, Inc., to Xilio’s board of directors.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that their interim update on the Phase 1/2 clinical trial of gavo-cel will be featured in the official Press Programme at the European Society for Medical Oncology.

Helius Medical Technologies, Inc. announced that it has received Breakthrough Designation from the U.S. Food and Drug Administration for its PoNS™ device with the proposed indication for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from stroke, to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over.

AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced the World Health Organization has published “adrulipase alfa” as the proposed International Nonproprietary Name for MS1819.

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced that the company entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations to advance the development of Gritstone’s CORAL COVID-19 vaccine program with an initial focus in South Africa.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced six data presentations at the American Academy of Orthopaedic Surgeons 2021 Annual Meeting scheduled to be held on August 31 to September 3 in San Diego.

Innoforce Pharmaceuticals, a biopharmaceutical innovation and partnership company, announces that it has opened a new Advanced Cell and Gene Therapy Development Facility in Hangzhou, China.